<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01153269</url>
  </required_header>
  <id_info>
    <org_study_id>KAL 1 HO</org_study_id>
    <nct_id>NCT01153269</nct_id>
  </id_info>
  <brief_title>Long-term Effectiveness and Safety in Hepatitis-co-infected Patients</brief_title>
  <official_title>Long-term Effectiveness and Safety in Hepatitis-co-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human
      Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus
      co-infected patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Baseline</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Baseline are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 4</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 4 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 12</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 12 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 24</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 24 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 36</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 36 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 48</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 48 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 60</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 60 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 72</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 72 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 84</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 84 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 96</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 96 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 108</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 108 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 120</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 120 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 132</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 132 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</measure>
    <time_frame>Week 144</time_frame>
    <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 144 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Baseline</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Baseline are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 4</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 4 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 12</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 12 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 24</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 24 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 36</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 36 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 48</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 48 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 60</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 60 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 72</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 72 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 84</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 84 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 96</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 96 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 108</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 108 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 120</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 120 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 132</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 132 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Week 144</time_frame>
    <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 144 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Baseline</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Baseline are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 4</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 4 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 12</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 12 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 24</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 24 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 36</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 36 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 48</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 48 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 60</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 60 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 72</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 72 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 84</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 84 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 96</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 96 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 108</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 108 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 120</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 120 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 132</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 132 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Cell Count</measure>
    <time_frame>Week 144</time_frame>
    <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 144 are presented.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">33</enrollment>
  <condition>Human Immunodeficiency Virus-Infection</condition>
  <arm_group>
    <arm_group_label>HIV-infected patients with hepatitis co-infection</arm_group_label>
    <description>HIV-infected patients with co-infections of Hepatitis B or Hepatitis C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir (Kaletra)</intervention_name>
    <description>3 capsules 2xdaily or 2 tablets 2xdaily Kaletra</description>
    <arm_group_label>HIV-infected patients with hepatitis co-infection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample, Human Immunodeficiency Virus-infected patients with Hepatitis B or C
        co-infections
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients infected by HIV-1 and HBV or HCV

          -  Age â‰¥18 years

          -  Patients who were initiated on a LPV/r containing antiretroviral (ARV) regimen

        Exclusion Criteria:

        - Contraindications as described in SmPC (summary of product characteristics) at the time
        of prescription
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Simianer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Germany, Medical Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27575</name>
      <address>
        <city>Berlin</city>
        <zip>10243</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27592</name>
      <address>
        <city>Berlin</city>
        <zip>10961</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27588</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27583</name>
      <address>
        <city>Frankfurt</city>
        <zip>60311</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27587</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27607</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5355</name>
      <address>
        <city>Krefeld</city>
        <zip>47800</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27604</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>June 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <results_first_submitted>November 16, 2011</results_first_submitted>
  <results_first_submitted_qc>November 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2011</results_first_posted>
  <last_update_submitted>November 16, 2011</last_update_submitted>
  <last_update_submitted_qc>November 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>Co-infection with Hepatitis B or Hepatitis C</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HIV-infected Participants With Hepatitis Co-infection</title>
          <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Analyzed</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Antiretroviral therapy break</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV-infected Participants With Hepatitis Co-infection</title>
          <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis Co-infection</title>
          <description>The number of participants with hepatitis B or hepatitis C co-infection.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chronic hepatitis B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic hepatitis C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of HIV infection</title>
          <description>How long participants had been diagnosed with HIV infection at Baseline. Based on 32 participants.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.7" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Baseline are presented.</description>
        <time_frame>Baseline</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Baseline are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Baseline.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" spread="63"/>
                    <measurement group_id="O2" value="69" spread="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 4 are presented.</description>
        <time_frame>Week 4</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 4 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 4.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="96"/>
                    <measurement group_id="O2" value="85" spread="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 12 are presented.</description>
        <time_frame>Week 12</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 12 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 12.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" spread="50"/>
                    <measurement group_id="O2" value="85" spread="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 24 are presented.</description>
        <time_frame>Week 24</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 24 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 24.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="94"/>
                    <measurement group_id="O2" value="97" spread="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 36 are presented.</description>
        <time_frame>Week 36</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 36.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 36 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 36.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" spread="33"/>
                    <measurement group_id="O2" value="75" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 48 are presented.</description>
        <time_frame>Week 48</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 48 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 48.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="41"/>
                    <measurement group_id="O2" value="79" spread="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 60 are presented.</description>
        <time_frame>Week 60</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 60.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 60 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 60.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="38"/>
                    <measurement group_id="O2" value="59" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 72 are presented.</description>
        <time_frame>Week 72</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 72.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 72 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 72.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="36"/>
                    <measurement group_id="O2" value="50" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 84 are presented.</description>
        <time_frame>Week 84</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 84.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 84 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 84.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="33"/>
                    <measurement group_id="O2" value="49" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 96 are presented.</description>
        <time_frame>Week 96</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 96.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 96 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 96.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" spread="44"/>
                    <measurement group_id="O2" value="63" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 108 are presented.</description>
        <time_frame>Week 108</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 108.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 108 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 108.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="19"/>
                    <measurement group_id="O2" value="43" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 120 are presented.</description>
        <time_frame>Week 120</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 120.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 120 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 120.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" spread="30"/>
                    <measurement group_id="O2" value="65" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 132 are presented.</description>
        <time_frame>Week 132</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 132.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 132 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 132.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" spread="24"/>
                    <measurement group_id="O2" value="51" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
        <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 144 are presented.</description>
        <time_frame>Week 144</time_frame>
        <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 144.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection: AST</title>
            <description>Aspartate aminotransferase (AST) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
          <group group_id="O2">
            <title>HIV-infected Participants With Hepatitis Co-infection: ALT</title>
            <description>Alanine aminotransferase (ALT) results for HIV-infected participants with hepatitis B or hepatitis C co-infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters</title>
          <description>The decision to perform aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory tests to monitor participants' liver function was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 144 are presented.</description>
          <population>Participants with aspartate aminotransferase and alanine aminotransferase results at Week 144.</population>
          <units>U/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="28"/>
                    <measurement group_id="O2" value="53" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Baseline are presented.</description>
        <time_frame>Baseline</time_frame>
        <population>Participants with HIV-1 RNA results at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Baseline are presented.</description>
          <population>Participants with HIV-1 RNA results at Baseline.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 4 are presented.</description>
        <time_frame>Week 4</time_frame>
        <population>Participants with HIV-1 RNA results at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 4 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 4.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 12 are presented.</description>
        <time_frame>Week 12</time_frame>
        <population>Participants with HIV-1 RNA results at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 12 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 12.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 24 are presented.</description>
        <time_frame>Week 24</time_frame>
        <population>Participants with HIV-1 RNA results at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 24 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 24.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 36 are presented.</description>
        <time_frame>Week 36</time_frame>
        <population>Participants with HIV-1 RNA results at Week 36.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 36 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 36.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 48 are presented.</description>
        <time_frame>Week 48</time_frame>
        <population>Participants with HIV-1 RNA results at Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 48 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 48.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 60 are presented.</description>
        <time_frame>Week 60</time_frame>
        <population>Participants with HIV-1 RNA results at Week 60.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 60 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 60.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 72 are presented.</description>
        <time_frame>Week 72</time_frame>
        <population>Participants with HIV-1 RNA results at Week 72.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 72 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 72.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 84 are presented.</description>
        <time_frame>Week 84</time_frame>
        <population>Participants with HIV-1 RNA results at Week 84.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 84 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 84.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 96 are presented.</description>
        <time_frame>Week 96</time_frame>
        <population>Participants with HIV-1 RNA results at Week 96.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 96 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 96.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 108 are presented.</description>
        <time_frame>Week 108</time_frame>
        <population>Participants with HIV-1 RNA results at Week 108.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 108 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 108.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 120 are presented.</description>
        <time_frame>Week 120</time_frame>
        <population>Participants with HIV-1 RNA results at Week 120.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 120 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 120.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 132 are presented.</description>
        <time_frame>Week 132</time_frame>
        <population>Participants with HIV-1 RNA results at Week 132.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 132 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 132.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 144 are presented.</description>
        <time_frame>Week 144</time_frame>
        <population>Participants with HIV-1 RNA results at Week 144.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>The decision to perform HIV-1 ribonucleic acid (RNA) tests to monitor participants' viral load was left to the treating physician's clinical judgment. The mean values and standard deviations for those tested at Week 144 are presented.</description>
          <population>Participants with HIV-1 RNA results at Week 144.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Baseline are presented.</description>
        <time_frame>Baseline</time_frame>
        <population>All participants with CD4+ cell count measurements at Baseline are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Baseline are presented.</description>
          <population>All participants with CD4+ cell count measurements at Baseline are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288" spread="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 4 are presented.</description>
        <time_frame>Week 4</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 4 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 4 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 4 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350" spread="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 12 are presented.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 12 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 12 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 12 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378" spread="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 24 are presented.</description>
        <time_frame>Week 24</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 24 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 24 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 24 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383" spread="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 36 are presented.</description>
        <time_frame>Week 36</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 36 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 36 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 36 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408" spread="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 48 are presented.</description>
        <time_frame>Week 48</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 48 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 48 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 48 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402" spread="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 60 are presented.</description>
        <time_frame>Week 60</time_frame>
        <population>All participants with CD4+ cell count measurements at Baseline are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 60 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Baseline are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424" spread="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 72 are presented.</description>
        <time_frame>Week 72</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 72 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 72 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 72 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431" spread="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 84 are presented.</description>
        <time_frame>Week 84</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 84 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 84 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 84 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405" spread="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 96 are presented.</description>
        <time_frame>Week 96</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 96 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 96 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 96 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503" spread="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 108 are presented.</description>
        <time_frame>Week 108</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 108 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 108 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 108 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581" spread="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 120 are presented.</description>
        <time_frame>Week 120</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 120 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 120 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 120 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="565" spread="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 132 are presented.</description>
        <time_frame>Week 132</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 132 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 132 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 132 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="502" spread="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Cell Count</title>
        <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 144 are presented.</description>
        <time_frame>Week 144</time_frame>
        <population>All participants with CD4+ cell count measurements at Week 144 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants With Hepatitis Co-infection</title>
            <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Cell Count</title>
          <description>The decision to perform laboratory tests to determine participants' CD4-positive (CD4+) T-lymphocyte counts was left to the treating physician's clinical judgment. The mean and standard deviation for those tested at Week 144 are presented.</description>
          <population>All participants with CD4+ cell count measurements at Week 144 are included.</population>
          <units>CD4+ cells/Î¼L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525" spread="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Investigators were instructed to report adverse events throughout the study (up to 3 years).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HIV-infected Participants With Hepatitis Co-infection</title>
          <description>HIV-infected participants with co-infections of hepatitis B or hepatitis C.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Raw (uncoded) terms</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>antiviral drug level above therapeutic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

